Clinical trials: COVID-19 Booster
SARS-CoV-2, COVID-19 Vaccine
Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination
This is a randomized, blinded, and dose escalation phase I trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT06167915
- Testing
- 30μg dose of LYB002V14, 60μg dose of LYB002V14
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19, SARS-CoV-2
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
The purpose of this study is to to evaluate the safety and immune response of COVI-VAC given as a single booster dose in healthy adults previously vaccinated against COVID-19 with an authorised mRNA or adenovirus-vectored…
- Trial name
- NCT05233826
- Testing
- COVI-VAC
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Immunogenicity, Safety
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
Primary#Objectives #Immunogenicity:To demonstrate the non-inferiority of binding antibody response in terms of geometric mean titers (GMT) of mRNA vaccine compare with mRNA COVID-19 vaccine(Pfizer) 14 days post dose.
- Conditions
- Immunogenicity, Safety, Efficacy
- Trial name
- NCT05686161
- Testing
- SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2., Pfizer(BNT162b2);SARS-Cov-2.
- Where
- Laos
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
COVID-19
Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
Open-label, prospective intervention study of IndoVac® as a single, homologous booster dose
- Trial name
- NCT05933278
- Testing
- SARS-CoV-2 Subunit Recombinant Protein Vaccine
- Where
- Indonesia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19 Booster, Spike Protein IgG Antibody
Profiling Spike Protein Antibody Response Post COVID-19 Booster
A descriptive study that will quantify the mean IgG antibodies remaining in vaccinated healthy participants after their COVID booster.
- Trial name
- NCT05476822
- Testing
- Obtain antibody titers
- Volunteers
- healthy volunteers welcome
- Sponsor
- David Grant U.S. Air Force Medical Center
COVID-19 Pandemic
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster
This is a randomized, double-blinded, placebo-controlled, dose-escalation study to valuate the safety and immunogenicity of RH109 as booster at 2 dose levels for ealthy adults who have received homologous or heterologous…
- Trial name
- NCT05609045
- Testing
- Lyophilized COVID-19 mRNA Vaccine, Sodium chloride
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wuhan Rhegen Biotechnology Co., Ltd.
Covid19
Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19
Multi-center phase Ib study to evaluate the Modified Vaccinia Virus Ankara (MVA) vaccine against SARS-CoV-2 in seronegative (Part A) and previously SARS-CoV-2-vaccinated individuals (Part B).
- Trial name
- MVA-SARS2-ST (NCT04895449)
- Testing
- MVA-SARS-2-ST
- Where
- 2 sites in Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
COVID-19
Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines
It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine…
- Trial name
- NCT05095298
- Testing
- Vaccine, COVID19
- Where
- 2 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
COVID - 19
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration…
- Trial name
- NCT06831786
- Testing
- Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial. The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral…
- Trial name
- NCT05465902
- Testing
- Recombinant COVID-19 variant Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated, mRNA COVID-19 vaccine (Moderna)
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19, Vaccine Reaction
A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine
This project is a prospective observational real-world study, recruiting and screening subjects who have completed 2 doses of the COVID-19 vaccine for more than 6 months and receive the third dose of the vaccine voluntarily into…
- Trial name
- NCT05493917
- Testing
- an inactivated SARS-CoV-2 vaccine named BBIBP-CorV
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
This study is a phase Ⅱ clinical trial to evaluate the safety and immunogenicity of SCTV01E-2 in people of different ages who had been vaccinated with COVID-19 vaccines.
- Trial name
- NCT05933512
- Testing
- SCTV01E-2, SCTV01E
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)
Aim: To investigate if a subcutaneous (s.c.) booster dose of 90 µg of the naked Akston AKS-452 vaccine (AKS-452X) at >= 3 months post initial vaccination, with any of the four registered vaccines, will boost the antibody titer…
- Trial name
- ACT-BOOSTER (NCT05124483)
- Testing
- AKS-452X
- Where
- Netherlands
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
COVID-19, SARS-CoV-2
Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05477186
- Testing
- CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg)
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
A phase Ⅱ, observer-blind, randomized, controlled, investigator-initiated clinical trial to evaluate the safety and immunogenicity of a booster vaccination with Recombinant COVID-19 vaccine (Sf9 Cell) in a population aged 18…
- Trial name
- NCT05463354
- Testing
- Recombinant COVID-19 Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Philippines
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
This was a randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety and immunogenicity of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen)…
- Trial name
- NCT05175625
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Cinnagen
COVID-19, Vaccine Adverse Reaction
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
The objective of this observational case-crossover study is to evaluate the effectiveness, safety and immunogenicity of the second booster dose in the elderly.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases
- Trial name
- Plus_Booster (NCT05283902)
- Testing
- ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
- Where
- Brazil
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
COVID-19, Vaccines
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
The safety and immunogenicity of AdCLD-CoV19-1 OMI (5.0x10^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated.
- Trial name
- NCT05576623
- Testing
- AdCLD-CoV19-1 OMI (Part A), AdCLD-CoV19-1 OMI (Part B)
- Where
- 7 sites in South Korea
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
COVID-19
Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
This study will address specific questions concerning the additional protection of the AZ COVID-19 vaccine as a second booster dose in preventing severe COVID-19 outcomes (hospitalisation, ICU admission etc) and will provide data…
- Trial name
- REFORCO-B (NCT05697705)
- Testing
- ChAdOx1 nCOV-19 vaccine (Vaxzeria), BNT162b2 (Pfizer), Ad26.COV2.S (Janssen)
- Where
- Brazil
- Volunteers
- 188,814,085 people
- Sponsor
- AstraZeneca